RNAC Stock Summary and Trading Ideas (Cartesian Therapeutics | NASDAQ:RNAC)

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Cartesian Therapeutics trades on the NASDAQ stock market under the symbol RNAC.

As of December 16, 2025, RNAC stock price declined to $8.32 with 145,371 million shares trading.

RNAC has a beta of 2.53, meaning it tends to be more sensitive to market movements. RNAC has a correlation of 0.32 to the broad based SPY ETF.

RNAC has a market cap of $216.34 million. This is considered a Small Cap stock.

Last quarter Cartesian Therapeutics reported $452,000 in Revenue and -$1.38 earnings per share. This beat revenue expectation by $225,464 and missed earnings estimates by -$.68.

The top ETF exchange traded funds that RNAC belongs to (by Net Assets): IWM, VTI, VXF, IWN, IBB.

RNAC has underperformed the market in the last year with a return of -55.5%, while the SPY ETF gained +13.1%. In the last 3 month period, RNAC fell short of the market, returning -15.0%, while SPY returned +2.6%. However, in the most recent 2 weeks RNAC has outperformed the stock market by returning +14.0%, while SPY returned -0.6%.

RNAC support price is $8.48 and resistance is $9.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNAC shares will trade within this expected range on the day.